1E Therapeutics
Drug development company creating first-in-class RNA-targeting therapeutics using a proprietary platform.
About
1E Therapeutics is a drug development company creating a novel class of programmable oligonucleotide therapeutics. Their patented platform autonomously and precisely silences disease-causing RNAs to treat intractable diseases, including genetically driven, infectious, and chronic conditions. This approach aims to deliver safer and more targeted therapies for a wide array of indications. Teams look it up for Drug Development, Life Sciences, Therapeutics.
Frequently asked
What does 1E Therapeutics do?
1E Therapeutics is a Drug Development company that offers Software. Teams look it up for Life Sciences, Therapeutics, RNA-Targeting. It was founded in 2020. Public records show about 49 people and $120M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has 1E Therapeutics raised?
1E Therapeutics has raised a total of $120M in funding. The most recent round on record is Seed.
When was 1E Therapeutics founded?
1E Therapeutics was founded in 2020.
What industry does 1E Therapeutics operate in?
1E Therapeutics operates in Drug Development, Life Sciences, Therapeutics, RNA-Targeting, Biotech.
How many employees does 1E Therapeutics have?
1E Therapeutics has approximately 49 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.